Adicet Bio Inc Dossier
Qualitative Analysis
Business overview
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company pioneering the discovery and development of allogeneic, off-the-shelf gamma delta T cell therapies engineered with chimeric antigen receptors (CARs). By utilizing V̄́1 gamma delta T cells, the company aims to combine the innate and adaptive immune properties of these cells to achieve durable clinical activity. Adicet's lead product candidate is prulacabtagene leucel (prula-cel, formerly ADI-001), an allogeneic CAR T cell therapy targeting CD20, which is being evaluated for the treatment of autoimmune diseases such as lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and rheumatoid arthritis (RA). The company is also developing ADI-212, a gene-edited and armored clinical candidate targeting prostate-specific membrane antigen (PSMA) for solid tumors.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the clinical development of lead candidate prula-cel (formerly ADI-001) from oncology into multiple B-cell mediated autoimmune indications, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS), anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV), and rheumatoid arthritis (RA).
Expected impact: Establishes first-mover advantage in allogeneic gamma delta CAR-T therapies for autoimmune diseases, addressing a massive global market with high unmet need.
Advancing the preclinical and clinical development of ADI-212, an allogeneic gamma delta CAR-T cell therapy candidate targeting PSMA for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Expected impact: Validates the utility of the gamma delta T-cell platform in solid tumors, diversifying the pipeline beyond hematological and autoimmune indications.
Collaborating with the FDA to align on and enable outpatient dosing of SLE and LN patients receiving prula-cel in clinical trials.
Expected impact: Significantly reduces the burden on healthcare infrastructure, lowers treatment costs, and increases patient accessibility compared to autologous CAR-T therapies that require hospitalization.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Completed tax filings and registration to transition the Adicet Variable Interest Entity (VIE) into a wholly owned subsidiary of Adicet Therapeutics, enabling continued research and development activities in China.
Financial impact: Did not have a material impact on the consolidated financial statements.
Strategic Partnerships
Provides Adicet with non-exclusive research and commercial rights to use MaxCyte's flow electroporation and ExPERT platform to increase the manufacturing efficiency and accessibility of its off-the-shelf nonviral gene therapies.
Terms: Adicet will pay platform licensing fees to MaxCyte.
Collaborating on the development of allogeneic gamma delta T-cell therapies, including ADI-002 (targeting GPC3 for hepatocellular carcinoma), which is fully funded by Regeneron.
Terms: Regeneron completely funds the licensed program, and Adicet is entitled to receive high single-digit royalties on future sales.